Inactive Instrument

Neuropathix, Inc.

Equities

NPTX

US64132Q1094

Biotechnology & Medical Research

Neuropathix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022

May 23, 2022 at 04:10 pm EDT

Neuropathix, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 0.20798 million compared to USD 0.032 million a year ago. Net loss was USD 1.6 million compared to USD 1.33 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.02 a year ago.

Latest news about Neuropathix, Inc.

Neuropathix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-23	CI
Neuropathix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-15	CI
Neuropathix, Inc. Auditor Raises 'Going Concern' Doubt	22-04-14	CI
Neuropathix, Inc. announced that it has received $0.15 million in funding	22-03-20	CI
Neuropathix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
Neuropathix, Inc. Appoints Michael Ropacki to its Scientific Advisory Board	21-08-12	CI
Neuropathix, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-06	CI
Neuropathix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-13	CI
Neuropathix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-30	CI
Neuropathix, Inc. announced that it has received $1.2075 million in funding from Lyons Capital, LLC	21-02-09	CI
Neuropathix, Inc. Appoints Daniel Richman to Board of Advisors	21-01-12	CI
Neuropathix, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-12	CI
Kannalife, Inc. has Changed its Name to Neuropathix, Inc	20-11-06	CI
Kannalife, Inc. has Changed its Name to Neuropathix, Inc	20-11-05	CI
Kannalife, Inc. Appoints Tage Honoré as the Chairman of the Company’s Board of Advisors	20-09-17	CI
Kannalife, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-12	CI
Kannalife, Inc. Bolsters IP Portfolio with Multiple Patents Issued in 12 Key European Territories	20-07-09	CI
Kannalife, Inc. Appoints Terrence O. Tormey to the Company’s Board of Advisors	20-06-02	CI
Kannalife, Inc. announced that it expects to receive $0.156 million in funding	20-06-01	CI
Kannalife, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-14	CI
Kannalife, Inc. Announces Results from Comparative UVB-Radiation Study on Atopidine™ Versus CBD	20-04-14	CI
Kannalife, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	20-03-30	CI
Kannalife, Inc. announced that it expects to receive $0.2 million in funding	20-03-11	CI
Kannalife, Inc. Strengthens Intellectual Property Portfolio with New Chinese-Issued Patent	20-02-20	CI
Kannalife, Inc. Announces Completion of NIH-NIDA Phase 1 Grant and Results from Lewis Katz School of Medicine at Temple University for the Potential Use of KLS-13019 in the Treatment of CIPN	20-02-11	CI

Chart Neuropathix, Inc.

Duration

Period

More charts

Company Profile

Neuropathix, Inc. is a biopharmaceutical company. It is focused on discovering, developing, and commercializing novel therapeutics from its proprietary synthetic cannabinoid derivative platform that are potentially useful for a range of inflammatory and neuropathic pain-related diseases. Its product candidates include KLS-13019 and KLS-13023. KLS-13019 can control mechanical sensitivity and inflammation associated with chemotherapy-induced peripheral neuropathy (CIPN) in the absence of tolerance development and also reduce opioid craving behavior. KLS-13023 is a drug candidate that includes synthetic cannabidiol (CBD) formulated in a gel capsule designed for potential use in humans. Its drug discovery platform potentially treats neurological and oxidative stress-related disorders, such as overt hepatic encephalopathy (OHE), chronic traumatic encephalopathy (CTE), and CIPN, with current good manufacturing practices (cGMP) pharmaceutical grade semi-synthetic and synthetic cannabinoids.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+0.70%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-8.52%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs